Clinical Trial Update: Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib [Phase 2]

View source ↗

Summary

A Phase 2 trial update for TQ-B3139 in ALK-positive non-small cell lung cancer patients who were previously treated with crizotinib; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TQ-B3139

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: ALK-positive NSCLC | Phase 2 | Status: UNKNOWN